An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of ProQuad When Administered by Intramuscular (IM) Route or Subcutaneous (SC) Route to Healthy Children Aged 12 to 18 Months
Latest Information Update: 06 May 2022
At a glance
- Drugs MMR-varicella zoster virus vaccine (Primary) ; MMR-varicella zoster virus vaccine (Primary)
- Indications Chickenpox; Measles; Mumps; Rubella
- Focus Pharmacodynamics
- Sponsors Merck Sharp & Dohme Corp.; sanofi pasteur MSD
- 01 Jul 2008 Actual end date changed from 1 May 07 to 1 January 2008, reported by Clinicaltrals.gov.
- 27 Oct 2007 Status changed from in progress to completed.
- 01 Mar 2007 New trial record.